Thalidomide
- 貨號 Cat. No.
- S1193
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
Thalidomide
Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.Phase 3.
| Size | Price | Stock | Quantity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Thalidomide was introduced as a sedative drug in the late 1950s. However, it was withdrawn due to a teratogenic effect on fetal development. Thalidomide binds to inactivate the protein cereblon, which is important to limb formation. [1]
There is now a growing clinical interest in thalidomide since it is introduced as an immunomodulatory agent used primarily, combined with dexamethasone, to treat multiple myeloma. The combination of thalidomide and dexamethasone, often in combination with melphalan, is now one of the most common regimens for patients with newly diagnosed multiple myeloma, with an improved response rate of up to 60-70%. [1]
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01927718 | Not yet recruiting | Myeloma | M.D. Anderson Cancer Center|Celgene Corporation | 2014-02 | |
| NCT01889420 | Not yet recruiting | Multiple Myeloma in Relapse | New Mexico Cancer Care Alliance|Novartis Corporation | 2014-02 | Phase 1 |
| NCT02018523 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | Baylor College of Medicine|Jun Zhang|Celgene Corporation | 2014-02 | Phase 1 |
| NCT01946152 | Not yet recruiting | Myeloma | M.D. Anderson Cancer Center|Celgene Corporation | 2014-02 | Phase 1|Phase 2 |
| NCT01996865 | Not yet recruiting | Lymphoma, Non-Hodgkin | Celgene Corporation | 2014-02 | Phase 3 |
Chemical Information
| Molecular Weight (MW) | 258.23 |
|---|---|
| Formula | C13H10N2O4 |
| CAS No. | 50-35-1 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Thalomid |
| Solubility (25°C) * | In vitro | DMSO | 52 mg/mL (201 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | 2 mg/mL (7 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol, | 5 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.25823 | 2.5823 | 5.1646 | 7.7469 |